Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Amifampridine in MuSK-MG and AChR-MG
NCT03579966Phase 3Terminated
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of amifampridine in myasthenia gravis (MG). Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 39 months. Started Jun 2018; status: terminated.
02
Drugs
amifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03579966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579966.